Human medicines European public assessment report (EPAR): Nucala, mepolizumab, Date of authorisation: 01/12/2015, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 76, Status: Authorised

EMA multi-stakeholder workshop on supporting innovation in cardiovascular medicines and medical devices in the EU, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 1 July 2026, 13:00 (CEST) to 2 July 2026, 16:00 (CEST)

Product Management Service (PMS) public API - Frequently asked questions (FAQs)

Human medicines European public assessment report (EPAR): Kaftrio, ivacaftor,tezacaftor,elexacaftor, Date of authorisation: 21/08/2020, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR): Alyftrek, deutivacaftor / tezacaftor / vanzacaftor, Date of authorisation: 30/06/2025, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Jinarc, tolvaptan, Date of authorisation: 27/05/2015, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Ryzneuta, efbemalenograstim alfa, Date of authorisation: 21/03/2024, Revision: 6, Status: Authorised

Opinion on medicine for use outside EU: Dengue Tetravalent Vaccine (Live, Attenuated) Takeda, Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated,Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated,Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated,Dengue virus, serotype 2, live, attenuated, Dengue, 13/10/2022 Positive opinion

Human medicines European public assessment report (EPAR): Febuxostat Viatris (previously Febuxostat Mylan), febuxostat, Date of authorisation: 15/06/2017, Revision: 16, Status: Authorised